Medtronic plc, a global leader in healthcare technology, has received the CE (Conformité Européenne) Mark for the expanded redo TAVI indication of its Evolut™ PRO+ and FX transcatheter aortic valve implantation $(TAVI)$ systems. This regulatory approval allows the implantation of a new Evolut transcatheter aortic valve inside any failed previously implanted TAV, regardless of the manufacturer. The redo TAVI procedure is specifically indicated for patients with severe aortic stenosis who are at high risk for open-heart surgery. This development provides a crucial new treatment option for patients with failing transcatheter heart valves, offering a minimally invasive alternative that underscores Medtronic's commitment to advancing patient care and expanding global treatment options.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.